Arrowhead Pharmaceuticals (ARWR) Land & Improvements (2021 - 2022)
Arrowhead Pharmaceuticals' (ARWR) quarterly Land & Improvements came in at $3.0 million in Q1 2022, little changed on a QoQ basis from $3.0 million in Q4 2021.
Powered by 
Analysis
Arrowhead Pharmaceuticals (ARWR) Land & Improvements (2021 - 2022) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 2 years of Land & Improvements data on file, last reported at $3.0 million in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Arrowhead Pharmaceuticals | 12.40 Bn | 10.80 Bn | - | - |